GLP-1 access in North Carolina: telehealth rules, licence lookups and Medicaid coverage

The card above is North Carolina's record from our state data file, and the sections below say what each line means and where it comes from. Rules on this page were checked on September 4, 2026; the linked sources are the authority if anything has moved since.

Who licenses prescribers in North Carolina

Physicians who treat patients located in North Carolina are licensed by the North Carolina Medical Board. The board's lookup is at portal.ncmedboard.org/verification/search.aspx, which loaded when we checked on September 4, 2026. Nurse practitioners are licensed by the state nursing board and physician assistants by the medical board or their own board, depending on the state; the prescriber licence explainer walks through each search and what an active record does and does not tell you. Cross-check the name against the federal NPI Registry, which lists every US prescriber with credential and practice location.

The pharmacy that fills the prescription is licensed by the North Carolina Board of Pharmacy. That includes pharmacies in other states that ship to a North Carolina address; they hold a non-resident licence from the same board. The Compounding Explained site covers what to search for once you are on the board site.

Telehealth prescribing in North Carolina

North Carolina does not require an in-person examination before a prescriber issues a prescription for a non-controlled drug after a telehealth visit. The Medical Board's position statement says a licensee-patient relationship may be established via synchronous or asynchronous telemedicine without any prior in-person meeting, and medications may be prescribed, provided the standard of care is met; it notes some situations (pain treatment, for example) may not suit telemedicine-only care. This is a board position statement, not a statute. The text we read is N.C. Medical Board Position Statement 5.1.4, Telemedicine (amended March 2024), a board policy statement rather than a statute, on September 4, 2026. The prescriber still has to meet the same standard of care as in an office, which for a GLP-1 means a real history, a weight and medication review, and a plan for follow-up.

North Carolina participates in the Interstate Medical Licensure Compact, the expedited licensing route for physicians who already hold a full licence in another member state. A compact licence is a full North Carolina licence and shows up on the board lookup like any other. Issuing letters of qualification and licences (Commission map dated January 1, 2026). None of this covers controlled substances, which add a federal layer; GLP-1s are not controlled. The cross-state telehealth explainer has the general pattern.

Medicaid and anti-obesity drugs in North Carolina

As of December 19, 2025, North Carolina Medicaid covered GLP-1s prescribed for obesity with prior authorization criteria published by the state. Source: NC Medicaid (NCDHHS): NC Medicaid to reinstitute coverage of GLP-1s for weight management, December 19, 2025. Coverage lapsed on October 1, 2025 during the state budget stalemate and was reinstated effective December 12, 2025 under the September 30, 2025 prior authorization criteria: Wegovy preferred, Zepbound and Saxenda non-preferred. Coverage of the same molecules for type 2 diabetes (Ozempic, Mounjaro) is a separate question and is usual. Federal law lets states exclude "agents used for weight loss" from Medicaid drug coverage (42 U.S.C. 1396r-8(d)(2)), which is why coverage varies state by state and can change with a budget. Managed-care plans in North Carolina may follow the state list or their own; the preferred drug list explainer shows where to look.

Compounded GLP-1s in North Carolina

We have not found a North Carolina-specific statute, rule or board notice on compounded GLP-1s that we could verify, so this page does not state one. The North Carolina Board of Pharmacy is the regulator for a 503A pharmacy in the state and for non-resident pharmacies shipping into it; its newsletters and board minutes are where a state position would appear. The federal baseline applies everywhere: FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, and after the enforcement-discretion periods it announced (503A pharmacies through February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide) pharmacies may not compound what is essentially a copy of an approved product outside the narrow exceptions in federal law (FDA statement). On March 3, 2026 FDA sent warning letters to 30 telehealth companies over the marketing of compounded GLP-1s (FDA press release). Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with Wegovy, Zepbound, Ozempic or Mounjaro.

Before you buy from a telehealth offer in North Carolina

1. Ask for the prescriber's full name and look it up on the North Carolina Medical Board lookup above. An active licence in North Carolina is the minimum, not an endorsement.
2. Ask which pharmacy will fill the prescription and check it on the North Carolina Board of Pharmacy site, including a non-resident licence if the pharmacy is elsewhere.
3. If the product is compounded, expect it to be described as compounded and not FDA approved, and ask for the certificate of analysis. The Compounding Explained site has a vetting checklist; the FormBlends regulatory status page tracks the federal position.
4. Price the offer against brand self-pay programs and other compounded programs using the GLP-1 Pricing Index and the FormBlends cost report, and use the clinic fit quiz to decide which care model suits you. If you are new to tirzepatide, the FormBlends tirzepatide introduction covers the drug itself, and the FormBlends directory lists licensed providers and pharmacies.